AAN and AHS Release Updated Adult Migraine Prevention Pharmacotherapy Guideline
This joint AAN/AHS guideline reorganizes migraine preventive selection around evidence confidence, tolerability, safety, and cost while integrating CGRP-targeted agents into first-line options for both episodic and chronic migraine.
AAN/AHS Migraine Prevention GuidelineAmerican Academy of NeurologyAmerican Headache SocietymigraineCGRP monoclonal antibodiesgepantstopiramatebeta blockersonabotulinumtoxinANeurology / Neuropharmacology
Background Information
New guidelines optimize migraine prevention with personalized strategies.
This guideline provides updated, evidence-based recommendations for pharmacologic migraine prevention in adults, addressing diverse scenarios such as comorbid conditions and special populations. The guidelines recommend when and how to initiate migraine preventive therapy, including choice of medication and considerations for fibromyalgia, obesity, and pregnancy. Pharmacists can enhance patient care by applying these guidelines to optimize migraine prevention, considering individualized patient factors and potential adverse effects. Updated guidelines aid in personalized migraine prevention, considering individual patient needs and comorbidities.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.